James D. Cox

James D. Cox's AcademicInfluence.com Rankings

James D. Cox

Medical

#1328

World Rank

#1654

Historical Rank

Oncology

#56

World Rank

#59

Historical Rank

medical Degrees

Download Badge

Medical

Why Is James D. Cox Influential?

(Suggest an Edit or Addition)

(See a Problem?)

James D. Cox's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) (1995) (4148)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial (2009) (1199)
Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. (1997) (1079)
Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. (2011) (983)
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. (1991) (413)
Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. (2005) (401)
Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. (1989) (368)
Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). (2005) (336)
Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. (1999) (334)
Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. (2007) (325)
Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410 (2000) (325)
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. (2006) (321)
Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy (2001) (316)
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. (1998) (294)
Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. (2007) (285)
Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. (2007) (284)
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. (2000) (283)
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. (2005) (281)
Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. (2004) (278)
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. (2010) (277)
2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma (2004) (268)
Clinical course of solitary extramedullary plasmacytoma. (1999) (252)
Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. (2010) (244)
Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? (2005) (240)
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. (2004) (224)
Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. (1993) (222)
Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. (2012) (221)
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. (2018) (208)
Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. (1995) (203)
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. (2006) (199)
4D Proton treatment planning strategy for mobile lung tumors. (2007) (194)
Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. (2000) (193)
Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy. (2004) (192)
Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. (2007) (186)
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (1997) (178)
The risk of developing a second cancer after receiving craniospinal proton irradiation (2009) (177)
Cranial irradiation in cancer of the lung of all cell types. (1981) (176)
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. (1998) (172)
The M. D. Anderson proton therapy system. (2009) (168)
Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. (2003) (167)
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. (2017) (167)
Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. (2004) (166)
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. (2004) (166)
Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. (1981) (165)
Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer (2011) (164)
Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. (2008) (164)
Long-term results with radiotherapy for Stage I-II follicular lymphomas. (2001) (164)
Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. (2000) (162)
Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. (2009) (160)
Near simultaneous computed tomography image-guided stereotactic spinal radiotherapy: an emerging paradigm for achieving true stereotaxy. (2003) (159)
Lymphoma of the nasal cavity and paranasal sinuses (1997) (157)
Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. (2005) (154)
Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. (2004) (153)
Should randomized clinical trials be required for proton radiotherapy? (2008) (150)
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). (2002) (146)
Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. (1979) (143)
Weekly localization films and detection of field placement errors. (1978) (140)
A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma (1998) (137)
Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. (2004) (137)
Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. (2009) (135)
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. (2003) (135)
Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. (2012) (135)
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. (1997) (134)
Standards for diagnosis and management of invasive breast carcinoma (1998) (133)
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. (2005) (133)
Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. (2007) (130)
Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. (2011) (128)
Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study (2017) (126)
Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer (2011) (126)
Primary malignant germinal tumors of the mediastinum. A study of 24 cases (1975) (126)
Are the results of RTOG 0617 mysterious? (2012) (122)
Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. (2014) (122)
Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. (2008) (120)
Predictors of postoperative complications after trimodality therapy for esophageal cancer. (2013) (120)
Localized primary malignant lymphoma of bone. (1997) (118)
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone (2002) (116)
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. (2005) (112)
Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. (1995) (109)
Image-guided radiation therapy for non-small cell lung cancer. (2008) (107)
Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report. (1987) (107)
Proton beam therapy and concurrent chemotherapy for esophageal cancer. (2012) (106)
Role of radiation therapy in small cell anaplastic carcinoma of the lung. (1983) (105)
Analysis of the probability and risk of cause-specific failure. (1994) (104)
Radiotherapy in the management of locally advanced lung cancer of all cell types: Final report of randomized trial (1981) (103)
The significance of needle biopsy after irradiation for stage c adenocarcinoma of the prostate (1977) (102)
Localized non‐Hodgkin lymphoma involving the thyroid gland (2001) (101)
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. (2007) (101)
interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts new evidence for accelerated proliferation from radiation therapy oncology group protocol 8313 (1992) (100)
Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. (2007) (100)
Esophageal cancer dose escalation using a simultaneous integrated boost technique. (2012) (98)
Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy (1995) (97)
Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. (1990) (96)
Metformin use and improved response to therapy in esophageal adenocarcinoma (2013) (95)
Thymoma: treatment and prognosis. (1992) (95)
ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. (1991) (94)
Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. (2012) (94)
On the interplay effects with proton scanning beams in stage III lung cancer. (2014) (93)
Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. (1990) (93)
Thymoma. A retrospective study of 87 cases (1994) (93)
Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer (2010) (91)
Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung (1979) (91)
Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. (2008) (89)
Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. (2005) (89)
Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. (2011) (88)
Superior sulcus tumors: Results of irradiation of 36 patients (1981) (88)
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. (2002) (87)
N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. (1991) (85)
A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non–Small Cell Lung Cancer (2005) (84)
Large‐dose fractionation. (Hypofractionation) (1985) (83)
Breast cancer: Is ethnicity an independent prognostic factor for survival? (1996) (83)
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. (2015) (83)
Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Preliminary report of a cooperative trial (1978) (81)
Characteristics of long‐term survivors after treatment for inoperable carcinoma of the lung (1985) (81)
Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M. D. Anderson Cancer Center. (2000) (80)
Localized primary non-Hodgkin lymphoma of the breast. (1998) (79)
Estimation of α/β for late rectal toxicity based on RTOG 94-06. (2011) (78)
Causes of treatment failure and death in carcinoma of the lung. (1981) (77)
Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. (2007) (77)
Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. (2006) (77)
Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. (2017) (76)
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. (2003) (76)
Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. (2006) (76)
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. (2003) (75)
Frequency of brain metastasis in adenocarcinoma and large cell carcinoma of the lung: correlation with survival. (1983) (74)
A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. (1986) (74)
Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. (2012) (71)
Radiotherapy Alone for Lymphocyte‐Predominant Hodgkin's Disease (2002) (71)
The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. (2003) (71)
Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials (1999) (71)
The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. (1991) (71)
Malignant lymphoma of the uterine cervix (1984) (71)
Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single-Institution Experience (2006) (71)
Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. (2003) (70)
RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? (2003) (70)
Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. (2014) (69)
Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer (2009) (69)
Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 9410) (2000) (69)
Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. (1997) (69)
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease (2002) (69)
NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (69)
Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. (2017) (68)
Improving radiation conformality in the treatment of non-small cell lung cancer. (2010) (66)
Results of whole-brain irradiation for metastases from small cell carcinoma of the lung. (1980) (65)
Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. (2004) (65)
Irradiation in the local control of malignant lymphoreticular tumors (non-Hodgkin's malignant lymphoma). (1974) (65)
The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol (1993) (65)
Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. (2003) (63)
Late rectal toxicity on RTOG 94-06: analysis using a mixture Lyman model. (2010) (63)
Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. (2013) (63)
Irradiation for bronchial carcinoma: Reasons for failure. I. Analysis of local control as a function of dose, time, and fractionation (1976) (62)
Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. (1993) (62)
Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity (2001) (62)
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy. (2006) (60)
Moss' radiation oncology : rationale, technique, results (1994) (60)
Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. (2009) (59)
Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. (2014) (59)
Factors influencing the development of lung fibrosis after chemoradiation for small cell carcinoma of the lung: evidence for inherent interindividual variation. (1998) (58)
Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. (2011) (58)
Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. (2001) (57)
Clinical report on the treatment of locally advanced lung cancer (1977) (56)
Toward consistent local control of certain malignant tumors. Endoradiotherapy with iridium 192. (1971) (56)
Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer (2012) (55)
Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. (2011) (55)
Aortic dose constraints when reirradiating thoracic tumors. (2013) (54)
Prospective Exploratory Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy with High-Dose Heart Exposure (2014) (54)
International prognostic index‐based outcomes for diffuse large B‐cell lymphomas (2002) (54)
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. (2013) (54)
Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, Stage III, predict long-term survival? (1981) (54)
Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. (1996) (54)
Patterns of failure in patients with inoperable carcinoma of the lung (1981) (53)
Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. (2010) (52)
A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls (2004) (51)
Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. (2004) (51)
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. (2004) (51)
The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies (1987) (50)
Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. (2012) (50)
Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. (2009) (49)
The role of local radiation therapy for mediastinal disease in adults with T‐cell lymphoblastic lymphoma (2002) (49)
Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma (1995) (49)
The role of radiotherapy in squamous, large cell, and adenocarcinoma of the lung. (1984) (49)
Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. (2003) (48)
Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. (2013) (48)
Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. (1997) (48)
Potential dosimetric benefits of four-dimensional radiation treatment planning. (2009) (47)
Correlation between lung fibrosis and radiation therapy dose after concurrent radiation therapy and chemotherapy for limited small cell lung cancer. (2001) (47)
109 RTOG 8808 ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable now small cell lung cancer with minimum three year follow-up (1995) (46)
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. (2004) (46)
Local control and survival after external irradiation for adenocarcinoma of the prostate. (1981) (46)
Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. (2004) (46)
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. (2006) (45)
Dose-time relationships and the local control of small cell carcinoma of the lung. (1978) (44)
Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. (2013) (43)
Ackerman and del Regato's cancer: Diagnosis, treatment, and prognosis (1977) (43)
Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? (2017) (43)
Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma (2004) (43)
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia (2004) (43)
Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Yes. (1983) (43)
Tolerance of pelvic normal tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the Radiation Therapy Oncology Group. (1988) (42)
Prognostic Significance of Total Lymphocyte Count, Neutrophil‐to‐lymphocyte Ratio, and Platelet‐to‐lymphocyte Ratio in Limited‐stage Small‐cell Lung Cancer (2019) (42)
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. (2001) (41)
Total dose, fraction size, and tumor volume in the local control of Hodgkin's disease. (1988) (40)
Radiation dosimetry and biodistribution of 99mTc-ethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer (2009) (40)
Radiochemotherapy of esophageal cancer. (2007) (40)
Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer. (2010) (40)
Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. (2011) (39)
The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. (2000) (39)
Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. (2016) (39)
Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiation therapy. (2013) (39)
Fit of a Generalized Lyman Normal-Tissue Complication Probability (NTCP) Model to Grade ≥ 2 Late Rectal Toxicity Data From Patients Treated on Protocol RTOG 94-06 (2007) (39)
Brain metastasis in patients with superior sulcus tumors (1987) (38)
Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. (2012) (38)
Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: preliminary report of a RTOG Pilot Study. (1985) (38)
Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas. (1988) (37)
Radiotherapy for lung cancer. (1985) (37)
Advanced carcinoma of the nasopharynx. 2. Pattern of failure in 256 patients. (1985) (37)
Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). (1986) (37)
Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. (2011) (37)
Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. (2007) (36)
Clinical research on the treatment of locally advanced lung cancer. Final report of VALG protocol 13 limited (1978) (36)
A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors (2012) (36)
Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report. (1994) (36)
Mammary carcinoma developing after radiotherapy and chemotherapy for Hodgkin's disease (1988) (36)
What is the lowest effective biologic dose for prophylactic cranial irradiation? (1985) (35)
Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. (1997) (35)
An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease (2002) (35)
Comparison of prognostic factors and survival among black patients and white patients treated with irradiation for non-small-cell lung cancer. (1992) (34)
Is immediate chest radiotherapy obligatory for any or all patients with limited-stage non-small cell carcinoma of the lung? Yes. (1983) (34)
Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. (2000) (34)
Primary non-Hodgkin lymphoma of the small bowel. (1999) (34)
Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. (2001) (34)
A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer: a 5-year follow-up report. (1998) (33)
Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. (1997) (33)
Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. (1999) (33)
Quantifying the interfractional displacement of the gastroesophageal junction during radiation therapy for esophageal cancer. (2012) (33)
High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. (1996) (33)
The management of superior sulcus tumors. (2000) (33)
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. (2003) (33)
Veterans administration lung cancer study group (1977) (32)
Presidential address: Fractionation: A paradigm for clinical research in radiation oncology (1987) (32)
Local control of squamous carcinoma of oral cavity and oropharynx with 3 vs 5 treatment fractions per week. (1977) (32)
Is long‐term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? (1992) (32)
Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). (2000) (32)
Status of particle therapy for lung cancer (2011) (32)
Interaction of thoracic irradiation and chemotherapy on local control and survival in small cell carcinoma of the lung. (1979) (31)
Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. (2017) (31)
Irradiation for inoperable carcinoma of the lung and high performance status. (1980) (31)
Single and double plane implants: a comparison of the Manchester System with the Paris System. (1984) (31)
Stage III nodular lymphoreticular tumors (non‐Hodgkin's lymphoma): Results of central lymphatic irradiation (1981) (31)
Biology-based combined-modality radiotherapy: workshop report. (2001) (30)
Association between Systemic Chemotherapy before Chemoradiation and Increased Risk of Treatment-Related Pneumonitis in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy (2008) (30)
Novel approaches to locally advanced unresectable non-small cell lung cancer. (2000) (29)
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. (2012) (29)
Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. (2002) (29)
Primary parotid lymphoma: the effect of International Prognostic Index on outcome. (1997) (29)
[Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials]. (2001) (28)
Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease (2004) (28)
Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. (2003) (28)
Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. (2016) (28)
The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol. (1993) (27)
Patterns of failure and results of preoperative irradiation vs radiation therapy alone in carcinoma of the pyriform sinus. (1980) (27)
Radiation therapy in the treatment of malignant fibrous histiocytoma. (1981) (27)
Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. (1997) (27)
The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the lung. (1981) (27)
Primary non-Hodgkin lymphoma of the large bowel. (1997) (27)
Complications of radiation therapy and factors in their prevention (1986) (27)
Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer (2015) (27)
Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. (2002) (27)
The lack of prognostic significance of biopsies after radiotherapy for prostatic cancer. (1983) (26)
Treatment planning for lung cancer: traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. (2003) (26)
Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior. (1997) (26)
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. (2001) (26)
Apoptosis and the Bcl-2 gene family -- patterns of expression and prognostic value in stage I and II follicular center lymphoma. (1999) (26)
Changes in the relative risk and sites of central nervous system metastasis with effective combined chemotherapy and radiation therapy for small cell carcinoma of the lung. (1983) (26)
Reduced fractionation and the potential of hypoxic cell sensitizers in irradiation of malignant epithelial tumors. (1980) (26)
Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. (2012) (26)
Acute radiation effects on cutaneous microvasculature: evaluation with a laser Doppler perfusion monitor. (1988) (25)
Multi-institutional clinical trials: 3-D conformal radiotherapy quality assurance. Guidelines in an NCI/RTOG study evaluating dose escalation in prostate cancer radiotherapy. (1996) (25)
Combination of a COX-2 Inhibitor With Radiotherapy or Radiochemotherapy in the Treatment of Thoracic Cancer (2003) (25)
O-035 Phase III trial of concurrent chemotherapy and radiotherapy(CT/RT) vs CT/RT followed by surgical resection for stage IIIa(pN2)non-small cell lung cancer (NSCLC): Outcomes and implications for surgical management in North American Intergroup 0139 (RTOG 9309) (2005) (24)
Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? (2009) (24)
Importance of Esophagogastroduodenoscopy in the Evaluation of Non‐Gastrointestinal Mucosa‐Associated Lymphoid Tissue Lymphoma (2003) (23)
FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy (2012) (23)
Total body irradiation vs. chemotherapy as a systemic adjuvant for small cell carcinoma of the lung. (1979) (23)
Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma (2001) (23)
Locally advanced adenocarcinoma of the endometrium: Results of irradiation with and without subsequent hysterectomy (1978) (22)
Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience. (1999) (22)
Preclinical biologic assessment of proton beam relative biologic effectiveness at Proton Therapy Center Houston. (2007) (22)
Five‐Year Survival After Hyperfractionated Radiation Therapy for Non‐Small‐Cell Carcinoma of the Lung (NSCCL): Results of RTOG Protocol 81–08 (1991) (22)
Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. (2000) (22)
Time dose relationships in adenocarcinoma. The importance of the interval to surgery following external pelvic irradiation (1978) (21)
Analysis of early and lats deaths on RTOG non-small cell lung carcinoma trials vs. CALGB 8433 (1991) (21)
Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. (2007) (21)
Comparison of surface doses from spot scanning and passively scattered proton therapy beams (2009) (21)
Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. (1998) (21)
Comparison of the radiation therapy oncology group and american joint committee on cancer staging systems among patients with non‐small cell lung cancer receiving hyperfractionated radiation therapy. A report of the radiation therapy oncology group protocol 83‐11 (1991) (21)
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. (2009) (21)
Radiation palliation of cervical cancer. (1996) (21)
Interfractional reproducibility of lung tumor location using various methods of respiratory motion mitigation. (2011) (20)
Local control of intrathoracic disease with chemotherapy and role of prophylactic cranial irradiation in small‐cell carcinoma of the lung (1981) (20)
Sociodemographic analysis of patients in radiation therapy oncology group clinical trials. (1998) (20)
Total pulmonary irradiation for metastases from testicular carcinoma. (1972) (20)
Is adenocarcinoma/large cell carcinoma the most radiocurable type of cancer of the lung? (1986) (19)
Hodgkin's disease stage I and II. A comparison between two different treatment policies (1977) (19)
Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. (1999) (19)
The role of thoracic and cranial irradiation for small cell carcinoma of the lung. (1981) (19)
Radiation dose escalation in non-small cell carcinoma of the lung. (2004) (19)
Recurrence patterns by treatment modality of carcinomas of the floor of the mouth and oral tongue. (1982) (19)
Carcinoma of the pancreas: results of irradiation for unresectable lesions. (1980) (19)
Randomized dose-searching phase ILE/II trials of fractionation in radiation therapy for cancer. (1991) (19)
Advanced carcinoma of the nasopharynx. A clinical study of 274 patients. (1982) (19)
Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. (2014) (19)
TGFβ1 Polymorphisms Predict Distant Metastasis–Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy (2013) (19)
Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. (2013) (19)
Evolution and accomplishments of the Radiation Therapy Oncology Group. (1995) (18)
Stage III follicular lymphoma: long-term follow-up and patterns of failure. (2003) (18)
Central lymphatic irradiation for stage I-III follicular lymphoma: report from a single-institutional prospective study. (2001) (18)
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy (2003) (18)
Cardiac localization of 99mTc-(Sn)-pyrophosphate following irradiation of the chest. (1977) (18)
Malignant lymphoid tumors of lymph nodes in the adult. (1974) (17)
Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. (2001) (17)
Paternalism, informed consent and Tuskegee. (1998) (16)
102 The value of regional nodal radiotherapy (dose/volume) in the treatment of unresectable non-small cell lung cancer: An RTOG analysis (1996) (16)
Age dramatically impacts on the quality-adjusted time without symptoms or toxicity (Q-Twist) in locally advanced non-Small cell lung cancer (LA-NSCLC)-a radiation therapy oncology group (RTOG) analysis (2000) (16)
The prognostic significance of flow cytometric DNA analysis (1992) (16)
Influence of preoperative irradiation on failures of endometrial carcinoma with high risk of lymph node metastasis (1984) (15)
The prognostic significance of histologic subtyping in small cell carcinoma of the lung (1984) (15)
Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma (1998) (15)
Radiation Therapy Oncology Group (RTOG) Altered Fractionation Trials (1995) (15)
Irradiation of bronchial carcinoma--II. Pattern of spread and potential for prophylactic irradiation. (1977) (15)
Evaluation of an ultrasound-based prostate target localization technique with an in-room CT-on-rails (2004) (15)
Influence of a sampling review process for radiation oncology quality assurance in cooperative group clinical trials--results of the Radiation Therapy Oncology Group (RTOG) analysis. (1995) (14)
Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. (2012) (14)
Preliminary report of toxicity following 3D Conformal Radiation Therapy (3DCRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy) (2001) (14)
Radiation Oncology; Rationale, Technique, Results, 9th edition (2010) (14)
Patients with Squamous Cell Carcinoma of the Head and Neck (2004) (14)
Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy (2014) (14)
Fractionation: a paradigm for clinical research in radiation oncology. (1986) (14)
Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome (1993) (14)
Preparing for the future of radiation oncology. (2007) (14)
Failure analysis of inoperable carcinoma of the lung of all histopathologic types and squamous cell carcinoma of the esophagus (1983) (14)
Utility of four-dimensional computed tomography for analysis of intrafractional and interfractional variation in lung volumes. (2008) (14)
In response to Bentzen et al., IJROBP 32:1531-1534; 1995. (1995) (13)
Central lymphatic irradiation to low dose for advanced nodular lymphoreticular tumors (non-Hodgkin's lymphoma). (1978) (13)
Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level IV (2002) (13)
Limited-stage small-cell lung cancer: patient survival after combined chemotherapy and radiation therapy with and without treatment protocols. (1995) (13)
Irradiation of stage I and II Hodgkin's disease. (1975) (12)
Changes of tumor motion patterns during a course of radiation therapy for lung cancer (2003) (12)
Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas (2002) (12)
Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. (2002) (12)
Internal mammary lymphoscintigraphy in patients with breast cancer. Correlation with computed tomography and impact on radiation therapy planning. (1983) (12)
PET/CT Fusion with Treatment Planning CT (TP CT) Shows Predominant Pattern of Locoregional Failure in Esophageal Patients Treated with Chemoradiation (CRT) is in GTV (2008) (12)
Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study (2017) (12)
Cure and follicular lymphoma. (1997) (12)
Impediments to Comparative Clinical Trials With Proton Therapy. (2016) (12)
Cisplatin and etoposide before definitive radiation therapy for inoperable squamous carcinoma, adenocarcinoma, and large cell carcinoma of the lung: a phase I-II study of the Radiation Therapy Oncology Group. (1986) (12)
Agreement rates among single photon emission computed tomography using gallium‐67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome (2000) (12)
4D CT-based Treatment Planning for Intensity-Modulated Radiation Therapy and Proton Therapy for Distal Esophagus Cancer (2008) (12)
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. (2006) (12)
Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial (2014) (12)
Role of radiation therapy to the brain in leukemic patients with cranial nerve palsies in the absence of radiological findings. (1999) (12)
Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma. (1998) (11)
Validation of a model-based segmentation approach to propagating normal anatomic regions of interest through the 10 phases of respiration. (2008) (11)
Prognostic factors in malignant lymphoreticular tumors of the small bowel and ileocecal region: a review of 50 case histories. (1979) (11)
Failure analysis in diagnostic and treatment strategies in cancer management (1983) (11)
The significance of needle biopsy after irradiation for stage C adenocarcinoma of the prostate. (1977) (11)
The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). (2001) (11)
Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. (1994) (11)
Clinical versus pathologic stage I and II Hodgkin's disease. (1980) (11)
Non-small cell lung cancer. Role of radiation therapy. (1986) (11)
Exclusion of Elective Nodal Irradiation Does Not Decrease Local Regional Control of Non-Small Cell Lung Cancer (2005) (11)
Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. (2012) (11)
Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. (1998) (11)
Cutaneous lymphoid hyperplasia: results of radiation therapy. (1985) (10)
Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". (2008) (10)
High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Non–Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy (2005) (10)
Incidence of Second Malignancy after Successful Treatment of Limited‐Stage Small–Cell Lung Cancer and Its Effects on Survival (2017) (10)
TRANSVAGINAL ROENTGEN THERAPY IN THE CONSERVATIVE MANAGEMENT OF CARCINOMA IN SITU OF THE UTERINE CERVIX. (1965) (10)
Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer (2011) (10)
Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. (1997) (10)
Time dose relationships in endometrial adenocarcinoma: importance of the interval from external pelvic irradiation to surgery. (1980) (9)
Dose-response in small cell carcinoma. (1988) (9)
PD4-1-6: Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLS): Reduction in incidence and severity despite higher doses (2007) (9)
Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis (2018) (9)
Integration of chemotherapy and radiation therapy for small cell carcinoma of the lung. (1982) (9)
Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). (2002) (9)
Image-Guided Radiotherapy of Lung Cancer (2007) (9)
SUV by FDG-PET predicts outcome of non-small cell lung cancer (2003) (9)
Target definition and contouring in carcinoma of the lung and esophagus. (2003) (9)
Induction chemotherapy for non-small cell carcinoma of the lung: limitations and lessons. (1991) (9)
Combined methotrexate and high‐dose vincristine chemotherapy with radiation therapy for small cell bronchogenic carcinoma (1985) (8)
A step toward ending the controversies in Hodgkin's disease. (1989) (8)
Intensity Modulated Proton Therapy for Head-and-Neck Cancer: The First Clinical Experience (2012) (8)
Uncertainties in physical and biological targeting with radiation therapy. (2003) (8)
Failure Patterns and Toxicity of Concurrent Proton Therapy and Chemotherapy for Stage III Non–small Cell Lung Cancer (2009) (8)
IMRT reduces lung irradiation in distal esophageal cancer over 3D CRT (2003) (8)
Initial evaluation of reduced fractionation in the irradiation of malignant epithelial tumors. (1976) (8)
Differences in Breast Cancer Treatment and Survival Between Older and Younger Women (1999) (8)
Update of toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 (2000) (8)
Interruptions of high-dose radiation therapy for non-small cell carcinoma of the lung decrease long-term survival in favorable patients (1992) (8)
Whole-limb irradiation of the lower calf using a six-field electron technique. (1996) (8)
The University of Texas M.D. Anderson Cancer Center Proton Therapy Facility (2003) (8)
Dose escalation by proton irradiation for adenocarcinoma of the prostate. (1995) (8)
Chapter 1 – Physical and Biologic Basis of Radiation Therapy (2010) (8)
Advanced carcinoma of the nasopharynx (1982) (8)
Evidence in oncology. The Janeway lecture 2000. (2000) (7)
Significantly Reduced Normal Tissue Dose with Proton Radiotherapy Compared with 3D-CRT or IMRT in Stage I or Stage III Non-Small Cell Lung Cancer (2005) (7)
Apparently localized and regionally advanced malignant lymphoreticular tumors in the adult. Early course following irradiation (1972) (7)
Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808. (2010) (7)
Time, dose, and fractionation in radiation therapy: an historical perspective. (1988) (7)
Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies. (1994) (7)
Preliminary results of biopsies following irradiation for locally advanced adenocarcinoma of the prostate. (1974) (7)
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. (2003) (7)
Chemoradiation for malignant epithelial tumors. (1998) (7)
Quantification of volumetric changes and internal organ motion during radiotherapy for prostate carcinoma using an integrated CT/linear accelerator system (2004) (7)
Radiation therapy can still be used safely in combined modality approaches in patients with Hodgkin's lymphoma. (2006) (7)
Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. (2008) (7)
Prognostic significance of interval from preoperative irradiation to hysterectomy for endometrial carcinoma (1984) (7)
Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma (2002) (7)
Combined radiation and chemotherapy for unresectable non-small cell lung carcinoma. (1994) (7)
Late effects of hyperfractionated-radiotherapy for head and neck cancer--in response to Drs. Withers and Taylor, IJROBP 32:887-888; 1995. (1995) (7)
Radiotherapeutic management of complications of carcinoma of the lung. (1982) (6)
Biopsies of non-small cell lung cancer: central review in cooperative studies of the Radiation Therapy Oncology Group. (1991) (6)
2485 : Preliminary Report of Image-Guided Hypofractionated Stereotactic Body Radiotherapy to Treat Patients With Medically Inoperable Stage I or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer (2006) (6)
Carcinoid tumors of the lung and family history of cancer. (1997) (6)
Preliminary Report of Radiation Pneumonitis (RP) in Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with Intensity Modulated Radiotherapy (IMRT) and Concurrent Chemotherapy (ConChT) (2005) (6)
Early Results of Stereotactic Body Radiation Therapy (SBRT) in Centrally/Superiorly Located Stage I or Isolated Recurrent NSCLC (2008) (6)
Acute Esophageal Reactions from Proton Beam Therapy and Concurrent Chemotherapy for Non-Small Cell Lung Cancer (NSCLC): Reduction in Incidence and Severity Despite Higher Doses (2007) (6)
Computed tomography in the staging of small cell lung cancer: implications for combined modality therapy. (1985) (6)
2463: Intra-Thoracic Patterns of Failure for Non-Small Cell Lung Cancer (NSCLC) With PET/CT-Defined Target Delineation (2006) (5)
Postgraduate training in radiation oncology in the United States, 1986. (1987) (5)
The science and art of radiation oncology after a century. (1999) (5)
Guidelines and Techniques for Image-Guided Radiotherapy for Non–Small Cell Lung Cancer (2007) (5)
1011 : A Review of the Activities of the ITC in Support of RTOG Advanced Technology Clinical Trials (2006) (5)
Multiagent chemotherapy, prophylactic neuraxis irradiation, and consolidative irradiation for small cell carcinoma of the lung (1985) (5)
Continuous split course irradiation for stage I and II Hodgkin's disease: 20 year experience at the Medical College of Wisconsin. (1994) (5)
Clinical Perspectives of Recent Developments in Fractionation (1992) (5)
Stage I and II breast carcinoma: treatment with limited surgery and radiation therapy versus mastectomy. (1990) (5)
Outcomes with Esophageal Cancer Radiation Therapy (2009) (5)
Management of unresectable non-small cell carcinoma of the lung (NSCLC). (2003) (5)
Concurrent Chemotherapy and Proton Beam Therapy for Esophageal Cancer (2009) (5)
The radiation therapy oncology group experience altered fractionation in lung cancer (1993) (5)
The respective roles of radiation therapy and chemotherapy in non-small cell carcinoma of the lung with mediastinal but not distant metastasis (N2M0) (1991) (5)
Hematologic recovery after central lymphatic irradiation for patients with stage I–III follicular lymphoma (2001) (5)
Automatic contouring of brachial plexus using a multi-atlas approach for lung cancer radiotherapy. (2013) (5)
Comparison of Tumor Shrinkage in Proton and Photon Radiotherapy of Lung Cancer (2007) (5)
Heart and Lung Radiation and Overall Survival in Non-small Cell Lung Cancer Patients After Chemoradiation Therapy (2012) (5)
Phase I clinical trial using selective cyclooxygenase-2 (COX-2) inhibitor celecoxib with concurrent thoracic irradiation in patients with poor prognosis non-small cell lung cancer (NSCLC) (2004) (5)
Erratum: Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer ( International Journal of Radiation Oncology Biology Physics (2004) 58 (1258-1267)) (2004) (5)
Intensity Modulated Proton Therapy Allows Dose Escalation and Normal-Tissue Sparing in Locally Advanced Distal Esophageal Tumors (2010) (5)
Does Adjuvant Hormonal Therapy Improve Freedom From Biochemical Relapse in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of RTOG 94-06 (2007) (5)
Phase II study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. (2011) (4)
111: V20 Predicts Fatal Pulmonary Toxicity After Extrapleural Pneumonectomy and Intensity Modulated Radiation Therapy (2006) (4)
Patterns of failure in treatment of stage I and II diffuse malignant lymphoid tumors. (1981) (4)
Therapeutic ratio and fractionation in cancer of the lung. (1988) (4)
Total central lymphatic irradiation for stage III nodular malignant lymphoreticular tumors. (1976) (4)
A Radiation Therapy Oncology Group experience: chemotherapy/radiation therapy of lung cancer (1993) (4)
Clinical science and patient care: lessons from cooperative randomized clinical trials. (1997) (4)
Extended‐Field Radiation Therapy for Prostatic Carcinoma with Para‐Aortic Lymph Node Metastasis (1986) (4)
Altered fractionation for non-small cell carcinoma of the lung. Rationale for the prospective trials of the Radiation Therapy Oncology Group. (1989) (4)
2727 : Impact of Respiration-Induced Tumor Motion Uncertainties on Adaptive Treatment Delivery Strategies: A Comparison Through Repeat 4D CT Imaging (2006) (4)
Long Term Outcomes Comparing Three-dimensional Conformal Radiation Therapy to Intensity Modulated Radiation Therapy with Concurrent Chemotherapy for the Treatment of Esophageal Cancer: The MD Anderson Experience (2011) (4)
2472 : The Volume of Lung Receiving low Radiation Doses Is Associated With Treatment Related Lung Toxicity When Irradiating Tumors in the Thorax (2006) (4)
Training in therapeutic radiology in the United States, 1984. (1985) (4)
Clinical implications of incorporating heterogeneity corrections in mantle field irradiation. (2003) (3)
O-152 Analysis of acute toxicity results of intensity modulated radiationtherapy (IMRT) in the treatment of non-small cell lung cancer (NSCLC) (2005) (3)
Design and Implementation of Clinical Trials of Ion Beam Therapy (2012) (3)
Carcinoma of the pancreas: Results of the conventional irradiation for unresectable lesions (1978) (3)
Alterations of fractionation. (1984) (3)
Brachytherapy in Lung Cancer (1986) (3)
96 Induction cisplatin/vinblastine decreased distant metastasis in unresectable squamous cell lung cancer (SCC): Failure patterns in RTOG 88-08/ECOG 4588 (1996) (3)
In response to Dr. Denham et al. (1996) (3)
Induction chemotherapy increased survival of patients with cancer of the esophagus treated with preoperative chemoradiation followed by surgery (2002) (3)
IMRT Versus Passively Scattered Proton Therapy (PSPT) for Locally Advanced NSCLC -- Impact of Changing Techniques and Technologies Over the Course of a Randomized Trial (2012) (3)
Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. (2007) (3)
Brief history of comparative clinical trials in radiation oncology: perspectives from the silver anniversary of the Radiation Therapy Oncology Group. (1994) (3)
Twice‐daily Thoracic Radiotherapy for Limited‐stage Small‐cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis (2018) (3)
Molecular Basis of Radiation Therapy (2008) (3)
Lung Cancer, Third Edition (2008) (3)
Radiotherapy in the management of advanced carcinoma of the nasopharynx (1980) (3)
Radiation Therapy Oncology Group (RTOG) trials for head and neck cancer. (2000) (3)
Current and future status of proton-beam radiation therapy in radiation oncology. (2007) (3)
In response to bentzen and thames: Regarding dose-response relationships for late radiation effects in the head and neck: Analysis of RTOG 8313 trial, fu et al. IJROBP 32:577–588; 1995 (1996) (3)
OC-0143: A Bayesian randomisation trial of IMRT vs. PSPT for locally advanced non-small cell lung carcinoma (2016) (3)
Interobserver Variability in Non-Small Cell Lung Cancer Target Delineation Among Thoracic Radiation Oncologists (2005) (3)
The Lung, Pleura, and Thymus (2010) (3)
Changes in Pulmonary Function after Three-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, or Proton Beam Therapy for Non-Small Cell Lung Cancer (2014) (3)
Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report. (1994) (3)
Proton Therapy vs. IMRT for Prostate Cancer: A Dosimetric Comparison (2007) (3)
The effect on toxicity of induction hormonal therapy in prostate cancer patients receiving dose escalated 3D conformal radiation therapy on RTOG 94-06 (2002) (3)
Should Randomized Clinical Trials Be Required for (2008) (3)
Absolute Lymphocyte Count Nadir During Chemoradiation as a Prognostic Indicator of Esophageal Cancer Survival Outcomes (2016) (3)
Completing Thoracic Radiation Therapy With Concurrent Chemotherapy Within 6 weeks Is Important for Reducing Distant Disease in Patients With Limited-Stage Small Cell Lung Cancer (2016) (2)
Immediately Concurrent Chemoradiation Therapy Is Associated With Improved 2-Year Overall Survival in Patients With Limited Small-Cell Lung Cancer (2016) (2)
Passing the baton--in a marathon. (2011) (2)
Methodology and research by the Radiation Therapy Oncology Group (RTOG). (2000) (2)
Interfraction interval is major determinant of late effects, but not acute effects or tumor control, with hyperfractionated irradiation (HFX) of carcinomas of upper respiratory and digestive tracts (URDT) (1990) (2)
Radiation therapy of cancer of the prostate. (1975) (2)
N2 (clinical) non-small cell carcinoma of the lung (NSCCL): Prospective trials of radiation therapy with total doses ≥ 60 GY by the radiation therapy oncology group (RTOG) (1989) (2)
Carcinomas of the oropharynx treated with hyperfractionated radiation therapy on Radiation Therapy Oncology Group Protocol 8313. (1994) (2)
On Equipoise and Emerging Technologies. Authors' reply (2008) (2)
Local control of intrathoracic and CNS sites with chemotherapy and prophylactic CNS irradiation in small cell carcinoma of the lung (1979) (2)
Oncology at the end of the century. (1999) (2)
Radiotherapy in the management of locally advanced lung cancer. Final report of randomized trial (1980) (2)
Evaluating Stereotactic Body Radiotherapy with Protons to Reduce Chest Wall Dose in the Treatment of Lung Cancer (2011) (2)
4-D CT Based and Daily In-room CT-guided Stereotactic Body Radiotherapy (SBRT) for Lung Cancer (2007) (2)
Factors Associated With Severe Pneumonitis for Limited Stage Small Cell Lung Cancer (2015) (2)
Adaptive / non-adaptive proton radiation planning and outcome in a phase II trial for locally advanced non-small cell lung cancer (2012) (2)
Radiation Time, Dose, and Fractionation in the Treatment of Lung Cancer (2011) (2)
Postoperative pulmonary complications following preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram (2002) (2)
WE‐E‐J‐6C‐06: Proton Treatment Planning for Mobile Lung Tumors (2005) (2)
Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer: In Reply to Dr. Armstrong (2007) (2)
Cervical Nodal Metastasis from an Unknown Primary Carcinoma (1989) (2)
Radioprotectors and Chemoprotectors in the Management of Lung Cancer (2011) (2)
Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience (2008) (2)
Importance of end points in determining effectiveness of thoracic irradiation for small cell lung carcinoma (1985) (2)
Gold medal award recipient (1994) (2)
Comprar Image-Guided Radiotherapy of Lung Cancer | Ritsuko Komaki | 9780849387838 | Informa Healthcare (2007) (2)
S11 5 MA – ALTERED FRACTIONATION RADIOTHERAPY-REPORT OF RTOG STUDIES (1991) (2)
A course in medical research study design and analysis. (1987) (2)
Concomitant adjuvant chemotherapy and radiotherapy for high risk breast cancer patients (2005) (2)
Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. (1999) (2)
Radiation oncology: postgraduate medical education in the United States, 1988. (1989) (2)
Predictive Dosimetric Factors for High-grade Esophagitis in Patients Treated for Non-small Cell Lung Cancer (NSCLC) with Definitive 3D Conformal Therapy (3D-CRT), Intensity Modulated Radiation Therapy (IMRT), or Proton Beam Therapy (PBT) (2010) (2)
PD-044 Optimal treatment for superior sulcus tumors (SST): Surgery first followed by adjunct RT/ChT improved survival for patients with resectable SST (2005) (2)
Proton beam radiation therapy in the treatment of cancer. (2004) (2)
PD-088 Image-guided proton radiotherapy for medically inoperable stage I non-small cell lung cancer (2005) (2)
Radiotherapy and Hodgkin's lymphoma. (2005) (2)
Dose-Volume Analyses of Grade ≥ 2 Late Rectal Toxicity Among Patients Treated on Protocol RTOG 94-06 (2007) (2)
Chemotherapy of small cell bronchogenic carcinoma (SCBC) with cytoxan (CTX), adriamycin (A), methotrexate (M), high dose vincristine (VCR) and consolidation radiotherapy (XRT) (1981) (2)
Induction or Concurrent Chemotherapy and Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer (1999) (2)
Molecular Response of Follicular Lymphoma to Cyclophosphamide, Doxorubicin, Vincristine, Prednisone C(H)OP or COP‐Based Therapy as Measured by Polymerase Chain Reaction Evidence of Translocation (14;18)(q32;q21) (2004) (2)
Preoperative radiation therapy of adenocarcinoma of the endometrium (1980) (1)
Circulating Lymphocyte Count During Neoadjuvant Chemoradiation Therapy for Esophageal Cancer as a Predictive Biomarker of Pathologic Complete Response. (2016) (1)
2223 Comparison of two different total body irradiation (TBI) fractionation regimens with respect to acute and late pulmonary toxicity (1999) (1)
Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC). (2010) (1)
233 speaker PROTONS COMPARED TO X-IMRT COMPARED TO 3D IN LOCALLY ADVANCED NSCLC (2011) (1)
Development of a successful outreach program at M. D. Anderson Cancer Center: a global perspective. (2008) (1)
Dosimetric Assessment of Daily Skin, Bone, Ultrasound and CT Alignment for Prostate Cancer IMRT (2005) (1)
Malt (mucosa associated lymphoid tissue) lymphoma with supradiaphragmatic presentation: Natural history and patterns of failure (1998) (1)
150 Serial determination of bcl-2 major breakpoint region (MBR) rearrangement, t(14;18) (q32;q21), in the bone marrow and peripheral blood for stages I – III follicular lymphoma after central lymphatic irradiation (CLI) — A preliminary report (1995) (1)
Reduced Incidence of Severe Acute Toxicities in Esophageal Cancer Treated with Proton Therapy (2015) (1)
Single Nucleotide Polymorphism at rs1982073:T869C of the TGF (cid:1) 1 Gene Is Associated With the Risk of Radiation Pneumonitis in Patients With Non–Small-Cell Lung Cancer Treated With Deﬁnitive Radiotherapy (2009) (1)
The 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy (2014) (1)
Incidence of and Survival Outcomes After Metachronous Second Primary Malignancy After the Treatment of Limited-Stage Small Cell Lung Cancer (2016) (1)
Analysis of Intra-Fractional Variations of Anatomy During Prostate IMRT Treatment (2005) (1)
Induction versus concurrent chemotherapy with radition therapy for unresectable non-small cell lung cancer (NSCLC) means competition between control of distant metastasis versus local/regional tumor (2000) (1)
Assessment of technological advances in radiation oncology: from whence comes the funding? (2008) (1)
Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial (2014) (1)
SU‐FF‐J‐104: Impact of Anatomical Changes On Dose Distributions During Three‐Dimensional Radiotherapy (3D‐CRT) of Lung Cancer: Preliminary Study Using Multiple 4‐DCT (2007) (1)
Phase III trial of amifostine with chemoradiation for inoperable non-small cell lung cancer (NSCLC): does amifostine protect cancer cells (2002) (1)
Intensity-Modulated Proton Therapy Reduces Normal Tissue Doses Compared with Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small Cell Lung Cancer: A Virtual Clinical Study (2010) (1)
The role of radiation therapy for carcinoma of the lung. (1981) (1)
Comprar Lung Cancer | Waun Ki Hong | 9781405151122 | Blackwell Publishing (2008) (1)
Heterogeneity measurements and calculations in the absence of complete build-up (1981) (1)
Uncertainties in contemporary treatment of aggressive lymphomas. (2003) (1)
Decreased Risk of Radiation Pneumonitis With Proton Beam Therapy in the Definitive Treatment of Non-Small Cell Lung Cancer (2015) (1)
Effect of treatment planning with computed tomography on prognosis of patients with inoperable carcinoma of the lung (1984) (1)
Poster PresentationThe 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy: Locally Advanced Non-Small Cell Lung Cancer (2014) (1)
International Clinical Trials in Radiation Oncology. Lung sites. (1988) (1)
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities (2018) (1)
Strategic plan for radiologic sciences: Outcome analysis (1984) (1)
2165 The role of the computerized axial tomography(CT) of the abdomen and pelvis in follow-up studies for the follicular lymphoma patients (1997) (1)
215 RTOG: Updated results of randomized trials (1996) (1)
2149 Determinants of lung fibrosis after chemoradiation for small cell carcinoma of the lung: Evidence for inherent interindividual variation (1996) (1)
SU‐GG‐T‐471: Potential Dosimetric Benefits of Four‐Dimensional Radiation Treatment Planning (2008) (1)
2161 The impact of radiation dose and fractionation on the risk factor of radiation pneumonitis on four radiation therapy oncology group (RTOG) lung cancer trials (1997) (1)
Comparing Risk Of Radiation Pneumonitis After Intensity-modulated Radiotherapy Vs. Proton Therapy (2014) (1)
1045 : p53 Polymorphisms Predict Poor Clinical Outcome in Non-Small-Cell Lung Cancer Patients Treated With Radiotherapy/Chemotherapy (2006) (1)
The Institute of Medicine, the National Cancer Institute, and clinical trials. (2011) (1)
2090 Radiation therapy oncology group: 3-D CRT quality assurance guidelines (1995) (1)
SU‐D‐BRC‐04: Comparison of Tumor Shrinkage in Proton and Photon Therapy of Lung Cancer (2011) (1)
1127: Socio-Demographic Predictors of Biochemical Failure and Survival Among High Risk Patients Treated on Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials: A Meta-Analysis (2006) (1)
Prevention of Diagnostic and Treatment-Related Sequelae in Stage I and II Hodgkin´s Disease (1999) (1)
Superior sulcus tumorsL results of irradiation f 36 patients (1980) (1)
FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy (2012) (1)
RTOG ALTERED FRACTIONATION TRIALS (1992) (1)
Incomparable report of clinical trial for locally advanced carcinoma of the prostate. (1993) (1)
15. Primary Malignant Lymphoma of the Central Nervous System: Results of Treatment of 11 Cases and Review of the Literature (1985) (1)
International Clinical Trials in Radiation Oncology. Time/dose/fractionation trials. (1988) (1)
Characteristics of Long‐Term Survivors after Irradiation for Inoperable Carcinoma of the Lung (1982) (1)
Radiation Therapy for Cancer The Fifteenth Anniversary of Hiroshima Cancer Seminar Foundation, the Seventeenth International Symposium of Hiroshima Cancer Seminar, November 2007 (2008) (1)
A festschrift for Philip Rubin (1997) (1)
Three-dimensional treatment planning for central lymphatic irradiation. (1999) (1)
Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer (2012) (1)
Over-representation of a polymorphism/missense mutation in the ataxia telangiectasia, mutated (ATM) gene in breast cancer patients versus controls (2001) (1)
Propensity score-based comparison of outcomes with 3D conformal radiotherapy (3D-CRT) versus intensity-modulated radiation therapy (IMRT) in treatment of esophageal cancer. (2012) (1)
THE MANAGEMENT OF SUPERIOR SULCUS TUMORS (2001) (1)
PD5-1-8: 4D CT imaging impacts lung volume definitions and dose-volume relationships in radiation treatment of non-small cell lung cancer (2007) (1)
TU-E-T-6C-02: Clinical Implementation of IMRT for Lung Cancers (2005) (1)
Group organizational structure (2001) (1)
Radiation therapy for carcinoma of the lung (2011) (0)
Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer (2010) (0)
Radiation therapy's contribution to local control and progression-free survival in patients with aggressive lymphomas (2000) (0)
Biology milestones of the IJROBP. (2005) (0)
One Cycle Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Associated with Improved Treatment Outcome in Patients with Limited Small-cell Lung Cancer (2008) (0)
Treatment outcome of irradiated esophageal cancer (2004) (0)
The Radiation Therapy Oncology Group: an outline of clinical research activities. (1988) (0)
In response to Prof. Huyskens (2003) (0)
A Comparison Of Strategies To Account For Bowel Filling In Patients Treated With Proton Therapy For Locally Advanced Distal Esophageal Cancer: A Planning Study (2011) (0)
Establishment of radiation resistant esophageal carcinoma cell lines and signal transduction pathways involved (2006) (0)
2462 : Induction Chemotherapy Improves Survival in Non-Squamous Unresectable Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation (2006) (0)
Clinical experiences in multi-institutional trials-RTOG (1993) (0)
Radiation Modality is a Strong Predictor for Postoperative Pulmonary and GI Complications After Trimodality Therapy for Esophageal Cancer (2012) (0)
The radiation therapy oncology group: An update of clinical research activities (1991) (0)
2167 Non-Hodgkin's lymphoma of the Waldeyer's ring(NHWR): Outcome for 110 patients with modern staging evaluation (1997) (0)
Weekly verification films and the detection of localization errors (1977) (0)
Mutagen sensitivity predicts poor overall and disease specific survival in patients with stage III non-small cell lung cancer treated with chemo/radiotherapy (2004) (0)
In defense of radiation therapy. (1973) (0)
2534 : Dosimetric Comparison of Conventional AP-PA Plus Oblique, 3D, Coplanar IMRT, and Non-Coplanar IMRT Techniques in the Treatment of Gastric Lymphoma (2006) (0)
Involved field radiotherapy after chop-based chemotherapy improves local control and freedom from progression in patients with bulky, clinical stage III-IV, intermediate grade of large-cell immunoblastic lymphomas (2000) (0)
Larry Emanuel Kun, March 10, 1946-May 27, 2018. (2019) (0)
Central lymphatic irradiation for stage III nodular lymphoma: An update (1991) (0)
Chapter 19 – The Lung, Pleura, and Thymus (2010) (0)
Primary C utaneous N on-Hodgkin's L ymphoma o f A nn A rbor Stage I : P referential C utaneous R elapses b ut H igh C ure Rate W ith D oxorubicin-Base d T herapy (2001) (0)
Analysis of Clinical and Dosimetric Factors Influencing Acute Esophagitis in Patients with Non-Small Cell Lung Cancer Treated with Concurrent Chemotherapy and Three Dimensional Conformal Radiotherapy (2005) (0)
2487 : The Effect of Number of Treatment Fields per Fraction on the Risk of Treatment Related Pneumonitis of Patients With Non-Small Cell Lung Cancer Treated by Concurrent Chemoradiation (2006) (0)
Diffusion Capacity of the Lungs Following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiation Therapy for Locally Advanced Non–small Cell Lung Cancer (2017) (0)
Inverse-probability weighted and propensity score-based analysis of long-term clinical outcomes comparing 3D conformal radiotherapy (3DCRT) with intensity-modulated radiation therapy (IMRT) in the treatment of esophageal cancer. (2012) (0)
Effect of technologic advancements in radiotherapy on postoperative pulmonary complications after neoadjuvant chemoradiation in esophageal cancer. (2012) (0)
17. Multiagent Chemotherapy with Prophylactic Neuraxis Irradiation and Consolidative Irradiation for Small Cell Carcinoma of the Lung (SCCL) (1985) (0)
Studies of acute radiation eftects on the cutaneous microvasculature using a laser doppler perfusion monitor (1987) (0)
Radiation therapy for malignant lymphoma: enduring importance in the era of systemic therapy. (2001) (0)
Radiotherapy Guidelines in Small Cell Lung Cancer (2007) (0)
3 VS. 5 fractions per week in bronchial carcinomas (1977) (0)
The Red Journal on its 30th anniversary. (2005) (0)
PD5-2-1: Effective local control of stage III non-small cell lung cancer (NSCLC) with accelerated radiotherapy for patients with unfavorable prognostic factors (2007) (0)
Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis (2018) (0)
Predictive Implications of KRAS and EGFR Gene Mutations in Non-small Cell Lung Cancer Treated with Radiation Therapy (2010) (0)
The Prognostic Factors of Lower Nadir of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio Were Associated With Worse Treatment Outcomes in Patients With Limited-Stage Small Cell Lung Cancer (2017) (0)
SU‐FF‐T‐105: Surface Doses Comparison for Spot Scanned and Passively Scattered Proton Therapy Beams (2009) (0)
Modality sequence and prophylactic cranial irradiation (PCI) are most significant in recursive partitioning analysis (RPA) of patients with limited small cell lung cancer (SCLC) treated with combined modality therapy (1998) (0)
Gender Differences in NSCLC Outcomes (2007) (0)
162 Quality assurance of 3-D conformal radiation therapy for a cooperative group trial — RTOG 3D QA center initial experience (1996) (0)
APhase IClinicalTrial ofThoracic Radiotherapy and Concurrent Celecoxib for Patientswith Unfavorable Performance Status Inoperable/Unresectable Non^Small Cell Lung Cancer (2005) (0)
175 Polymorphism at the 3′-utr of the thymidylate synthase (tyms) gene, a potential predictor for outcomes: Of patient with esophageal adenocarcinoma treated with preoperative chemoradiation (2006) (0)
1039 : 4D CT Derived Ventilation IMRT Avoidance in Locally Advanced NSCLC (2006) (0)
Mid-course resimulation for small cell lung cancer patients receiving definitive chemoradiation: sparing of normal lung and esophagus without decrement in local control: PD6-1-6 (2007) (0)
IClinicalTrial ofThoracic Radiotherapy and Concurrent Celecoxib for Patientswith Unfavorable Performance Status Inoperable / Unresectable Non ^ Small Cell Lung Cancer (2005) (0)
Radiation therapy for stage I and II primary large B-cell lymphoma of the mediastinum (1998) (0)
Risk Factors Predicting Failure and Survival in Lung Cancer Patients Treated With Definitive Dose-Escalated Proton Radiation Therapy (2013) (0)
Patient-reported symptom burdens in NSCLC patients undergoing proton, 3DCRT, or IMRT. (2013) (0)
Prophylactic Cranial Irradiation is More Important to Improve the Overall Survival among Patients with Limited Small–cell Lung Cancer Who Received One-Cycle Induction Chemotherapy and Had Complete Response to Therapy (2009) (0)
2150 Long term observations in combined modality therapy for limited stage small cell lung cancer (1997) (0)
O-142 Comparison of outcomes for patients with medically inoperablestage I non-small cell lung cancer treated with two-dimensional versus three-dimensional radiotherapy (2005) (0)
Effects of Amifostine on Acute and Late Toxicity of Radiotherapy and Concurrent Chemotherapy for Local Advanced Non-Small Cell Lung Cancer (2007) (0)
SU‐FF‐J‐29: Quantification of 4DCT Determined Lung Tumor Motion Based On Image Registration (2005) (0)
Duration of Thoracic Radiation Therapy With Concurrent Chemotherapy Is Important for the Outcome of Patients With Limited-Stage Small Cell Lung Cancer (L-SCLC) (2013) (0)
Comparison of Toxicity Scoring Systems for Radiation Pneumonitis: Impact on Risk Estimates among Patients with Non-small Cell Lung Cancer (2008) (0)
How Often Does 18F-FDG PET Scan Change Management During Treatment of Hodgkin Lymphoma (HL)? (2007) (0)
Are patients with supraclavicular node metastases in non-small cell lung cancer (NSCLC) curable with chemoradiotherapy? (1998) (0)
History, protocols, and the team. (2003) (0)
PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib (2015) (0)
The role of radiation therapy in carcinoma of the pyriform sinus (1979) (0)
Predictors of Brain Metastasis After Prophylactic Cranial Irradiation for Limited-Stage Small Cell Lung Cancer (2014) (0)
HighMutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage IIINon^Small Cell Lung Cancer Treatedwith Radiotherapy and Chemotherapy (2005) (0)
RESPONSE TO MACBETH AND PRICE CONCERNING OUR PAPER “Novel approaches to locally advanced non-small cell lung cancer” (2001) (0)
SU‐FF‐T‐340: Effect of Marker Implants On Dose Distribution in Proton Therapy (2005) (0)
Ki-67, p53 and bcl-2 expression as prognostic indicators for patients with resectable brain metastasis from non-small cell lung cancer (2001) (0)
Prognostic factors in malignant lymphoreticular tumors of the small bowel and ileocecal region: A review of 50 cases (1978) (0)
Radiotherapy Alone for Lymphocyte Predominant Hodgkins Disease: 9:07 AM (12) (2002) (0)
Impediments to Comparative Clinical Trials With (2016) (0)
TH‐C‐ValB‐06: Thoracic Proton Treatment Planning Strategies Based On the 4D CT Information (2006) (0)
Interfractional Reproducibility of Gastro-Esophageal Junction (GEJ) Location for Patients with Esophageal Cancer (2011) (0)
Poster PresentationComparing Risk of Radiation Pneumonitis After Intensity Modulated Radiation Therapy Versus Proton Therapy: Locally Advanced Non-Small Cell Lung Cancer (2014) (0)
MTP20-01: Image guided radiation therapy: the path to protons (2007) (0)
An Analysis of Adaptive Proton Planning in a Phase II Trial For Locally Advanced Non-small Cell Lung Cancer (2011) (0)
PD5-2-6: Hypofractionated stereotactic body radiotherapy in patients with peripherally or centrally located medically inoperable stage I or isolated recurrent non-small cell lung cancer (2007) (0)
Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung: Preliminary report of a cooperative trial (1977) (0)
The role of local radiation in mediastinal T-cell lymphoblastic lymphoma (2000) (0)
Non-Smokers and Former Smokers at Increased Risk for Treatment Related Pneumonitis (TRP) in Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC) (2007) (0)
Risk Factors for Grade 2+ Late Bladder Toxicity among Patients Treated on Protocol RTOG 94-06 (2008) (0)
Dosimetry review process for head and neck (H&N) cancer trials conducted by radiation therapy oncology group (RTOG) (1989) (0)
Experimental Evaluation of the Interplay Effect of Scanning Proton Beam for Small Moving Target in Heterogeneity Using a 4-dimensional Phantom (2012) (0)
Radiation oncology. (1991) (0)
Abstract P2-02-21: Longitudinal analysis of circulating tumor cells and cell free tumor DNA by next generation sequencing in triple negative breast cancer (2016) (0)
The role of craniospinal irradiation (csi) in adults with central nervous system (cns) recurrence of leukemia (2003) (0)
Definition and Management of Superior Sulcus Tumors (2018) (0)
Reirradiation With Proton Beam Therapy or Intensity Modulated Radiation Therapy for Non-small Cell Lung Cancer: An Institutional Experience (2012) (0)
Dose-Volume Analyses of Postoperative Lung Complications in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy Followed by Surgery (2005) (0)
SU-FF-T-344: Impact of Inter-Fractional Motion of the Anatomy On Prostate Proton Dose (2005) (0)
Effects of Inter-Fraction Anatomic Changes on Proton Therapy Dose Distributions in Lung Cancer (2007) (0)
354 TOXICITY AND PATTERNS OF FAILURE OF ADAPTIVE PROTON THERAPY (2012) (0)
Assessing the Impact of Technological Advancement on Outcome for Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Concomitant Chemoradiotherapy (2007) (0)
Poster ViewingReported Outcomes and Toxicities for Inoperable, Stage II-III Non–Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity Modulated Proton Therapy (2017) (0)
1764: Long-term Toxicity following 3D Conformal Radiation Therapy for Prostate Cancer on RTOG 9406, a Phase I/II dose Escalation Study (2007) (0)
A Survey of the ITC Volumetric Treatment Planning Data Archive Supporting RTOG Advanced Technology Clinical Trials (2007) (0)
OC-0499 PROGNOSTIC IMPACT OF RADIATION THERAPY TO THE PRIMARY TUMOR IN PATIENTS WITH OLIGOMETASTATIC LUNG CANCER (2012) (0)
Similar Outcomes of Solitary Plasmacytoma of Bone (SPB) after Irradiation of Localized Tumor or Entire Medullary Cavity: P-40 (2002) (0)
Treatment of cancer of the lung. (1986) (0)
Chapter 20 – The Esophagus (2010) (0)
Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy (2012) (0)
Analysis of in-field control and late complications in adults with 533 Hodgkin’s disease sites treated with combined modality therapy (2001) (0)
Methodology for assessing long-term complications in clinical trials (1985) (0)
Treatment for superior sulcus tumors (SST): Effect of surgery first followed by adjunct concurrent chemoradiotherapy on survival of patients with marginally resectable SST. (2010) (0)
Longitudinal study of pneumonitis and esophagitis-related symptoms in patients receiving concurrent chemoradiation for NSCLC. (2015) (0)
Evaluation of Residual Deviation in Patient Positioning and its Impact on Dose Distribution for Proton Radiotherapy (2007) (0)
Individualized Radiotherapy by Dose Escalation and Altered Fractionation in Non‐Small Cell Lung Cancer (2014) (0)
FDG Uptake Predicts Recurrence and Survival in Patients with Unresectable Stage III Non-small Cell Lung Cancer Treated with 74 Gy (RBE) Proton Therapy and Chemotherapy (2011) (0)
PD5-1-3: What effects do anatomic changes during treatment have on target and normal tissue dosimetry parameters of lung cancer radiotherapy? A multiple 4DCT analysis (2007) (0)
Hematological recovery after central lymphatic irradiation (CLI) for stage I–III follicular lymphoma (2000) (0)
Concurrent chemo-radiation results in equivalent local and overall outcome as induction chemotherapy followed by surgery for clinical stage IIIA non-small cell lung cancer (2002) (0)
SP-0417 PARTICLE THERAPY FOR LUNG CANCERS (2012) (0)
P-959 A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC) (2005) (0)
Kie Kian Ang, M.D. Ph.D., 1950–2013 (2013) (0)
An association of prior therapeutic chest irradiation and 99m Tc pyrophosphate uptake in the heart (1978) (0)
Abstract 4842: Pharmacodynamic stratification of metastatic colorectal cancer patients using genomic datasets (2015) (0)
Radiation enhances engraftment of mesenchymal stem cells in murine 4T1 tumors (2007) (0)
Continuous split course irradiation for stage I and II hodgkin's disease: 20 year experience at the medical college of Wisconsin (1994) (0)
Cranial Irradiation for Lung Cancer-Reply (1981) (0)
Abstract 1609: Comprehensive multi-omic analysis of circulating tumor cells isolated from a metastatic triple-negative breast cancer patient to identify pathogenic genomic aberrations (2015) (0)
OC-0496 RISK FACTORS FOR LOCAL AND REGIONAL RECURRENCE IN PATIENTS WITH RESECTED N0-N1 NON-SMALL CELL LUNG CANCER (2012) (0)
2117 : Significantly Reduced Lung and Heart Dose With Proton Radiotherapy Compared With IMRT for Esophageal Cancer (2006) (0)
Improving the Quality of Radiation Oncology Education Through an Innovative Medical Student Treatment Planning Curriculum (2014) (0)
Non-small Cell Lung Cancer* Role of RadiationTherapy (2017) (0)
The role of radiotherapy in treatment of malignant fibrous histiocytoma (1979) (0)
Evaluation of conventional radiotherapy vs. conformal radiotherapy in the treatment of non-small-cell lung cancer after surgical resection (2007) (0)
Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer (2014) (0)
81 Apoptosis, mitosis, BCL-2, bax, and BCL-X as predictors of tumor response in stage I and II follicular lymphoma (1997) (0)
Recurrence patterns by treatment group in carcinoma of the floor of mouth and mobile tongue (1981) (0)
Treatment and long-term outcome of stage II Hodgkin's disease - 30 years experience at M.D. Anderson Cancer Center (2000) (0)
Long-term outcomes of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer (2017) (0)
Phase-by-phase Reproducibility of Thoracic Anatomy Based on 4D-CT Imaging and Effects on Resultant Internal Target Volumes (ITV) (2008) (0)
Clinical summary: The challenge of local tumor control and its impact on survival (1986) (0)
Prognostic factors identified in the long term survivors with limited small cell lung cancer (2008) (0)
2145: Risk Factors for Pericardial Effusion in Esophageal Cancer Treated With Definitive Chemoradiation Therapy (2006) (0)
WE‐E‐ValA‐02: Dosimetric Comparison of the No Action Level Alignment Protocol with Daily Alignment Techniques for Prostate Cancer (2006) (0)
Setup Margins for Gated Treatment of Lung Tumors (2009) (0)
Abstract2521: Comparison of 18F-FDG PET Scan With 67Ga-citrate Scan for Imaging of Diffuse Large B-Cell Lymphoma/ a Prospective Study (2006) (0)
lLong-Term Outcomes after Proton Therapy, with Concurrent Chemotherapy, for Stage II-III Inoperable Non-Small Cell Lung Cancer (2016) (0)
Particle Therapy Clinical Trials (2018) (0)
The Pattern of Recurrence in Esophageal Cancer Patients Treated with Concurrent Chemoradiation with or without Surgery (2008) (0)
Cancer Journal: From the guest editor (2003) (0)
Incidence and Risk Factors for Acute Esophagitis in Inoperable Non-small Cell Lung Cancer Patients Treated with Definitive Radiation Therapy (2008) (0)
Obituary--Kie Kian Ang, MD, PhD, FACR, FASTRO. (2013) (0)
Incidence and Survival of Patients who Developed Limited-Stage Small Cell Lung Cancer after Successful Treatment of a Previous Cancer (2018) (0)
Failure Patterns and Toxicity After Chemoradiation with 74 Gy(RBE) for Non-small Cell Lung Cancer (2011) (0)
345 Long-term survival outcome of patients with inoperable non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy with oral etoposide and cisplatin (1997) (0)
"Non"-malignant tumors. (1981) (0)
Brachytherapyin Lung Cancer (2017) (0)
Mutagen Sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. (2004) (0)
Thymic neoplasms. (1997) (0)
Reduced Normal Tissue Dose and Individualized Radical Radiotherapy by Intensity Modulated Proton Therapy Compared with Intensity Modulated Photon Therapy in NSCLC (2008) (0)
Improved 5-Year Disease Free-Survival and Distant Metastasis-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer Who Had 18F-fluorodeoxyglucose Positron Emission Tomography (PET) or PET/CT Before Chemoradiation Therapy (2013) (0)
QUANITY OF RADIATION RECEIVED BY THE CONTRALATERAL LUNG PREDICTS FATAL PULMONARY EVENTS AFTER INTENSITY MODULATED RADIATION THERAPY FOLLOWING EXTRAPLEURAL PNEUMONECTOMY FOR MESOTHELIOMA (2006) (0)
A Prospective Analysis of Cardiac Biomarkers and Electrocardiogram Abnormalities in Patients Receiving Thoracic Radiation Therapy With High-Dose Heart Exposure (2014) (0)
Supine positioning reduces lung volumes irradiated in patients treated for esophageal cancer (2003) (0)
Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time Periods (2011) (0)
Randomized study to evaluate efficacy of levamisole in patients with unresectable non-oat cell carcinoma of the lung treated with radiation therapy (1984) (0)
2094 : Association Between Induction Chemotherapy and Increased Risk of Treatment Related Pneumonitis in Esophageal Cancer Patients Treated With Concurrent Chemoradiotherapy (2006) (0)
Malignant lymphoreticular tumors originating in the small bowel Natural history, response to treatment and evaluation of current staging systems (1977) (0)
Association between Treatment-related Pneumonitis and the Overall Survival after Definitive Radiotherapy for Non–small Cell Lung Cancer (2009) (0)
PD-074 Does response rate in the induction chemotherapy predictsurvival for locally advanced non-small cell lung cancer (LANSCLC)?: Secondary analysis of RTOG 8804/8808 (2005) (0)
The Radiation Therapy Oncology Group: an update of clinical research activities. (1991) (0)
Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer : Small Cell Lung Cancer (2014) (0)
119 : Predictors of Late Toxicities and Symptom Clusters in Radiation Therapy Oncology Group (RTOG) Prostate Cancer Trials of High Risk Patients: A Meta-Analysis of Physician Rated Toxicities (2006) (0)
Long-Term F ollow-Up o f a P rospective S tudy o f C ombined Modality T herapy f or S tage I -II I ndolent N on-Hodgkin's Lymphoma (2003) (0)
530 Long-term survival outcome of patients with inoperable non-small cell lung cancer (NSCLC) following concurrent chemoradiation therapy with oral etoposide and cisplatin (1997) (0)
Heterogeneous planning for homogeneous protocols. (2004) (0)
19 Translational research: Transforming the role of biomedical publishing (2006) (0)
A Comparison of Outcomes in Patients with Pathological Stage I-IIIB Non-Small Cell Lung Cancer Treated with Postoperative Two- or Three-Dimensional Conformal Radiotherapy (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With James D. Cox?

James D. Cox is affiliated with the following schools:

MD Anderson Cancer Center
Kobe University
University of Washington

James D. Cox's Academic­Influence.com Rankings

Why Is James D. Cox Influential?

James D. Cox's Published Works

Published Works

What Schools Are Affiliated With James D. Cox?

James D. Cox's AcademicInfluence.com Rankings